title: A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
abstract: OBJECTIVE
  To investigate the association between a single-nucleotide polymorphism (SNP) of ERCC1, Asn118Asn (C → T), and the response of patients with late-stage non-small cell lung cancer (NSCLC) (n = 142) to cisplatin-based chemotherapy.
  
  
  METHODS
  The SNP, Asn118Asn (C → T), in codon 118 of ERCC1 was detected using an AllGlo™ Probe-based real-time PCR kit. The short-term clinical outcomes were evaluated by measuring complete and partial responses (CR and PR), whereas progression-free survival (PFS) and overall survival (OS) were determined to indicate long-term outcomes.
  
  
  RESULTS
  The allelic frequencies of the ERCC1 codon 118 were found to be 60.6% (C/C), 33.1% (C/T), and 6.3% (T/T), respectively. Overall, the CR and PR to cisplatin-based treatment were 33.1%. Notably, the response rate of patients carrying an ERCC1 118 C/C allele was more than twofold higher than that of patients with a C/T or T/T genotype (95% confidence interval (CI), 1.065-3.910, P = 0.032). Correspondingly, the long-term median PFS and OS of patients carrying the ERCC1 118 C/C allele were significantly longer than those of patients carrying a C/T or T/T allele (P < 0.01). Besides, positive correlation was observed between the differentiation status and tumor staging as well as the C/C genotype.
  
  
  CONCLUSIONS
  Our results suggest that this polymorphism of ERCC1 at codon 118 is associated with patient response to cisplatin-based chemotherapy in treatments of late-stage NSCLC. Moreover, by assaying this SNP in blood cells, the ERCC1 codon 118 may represent a valuable biomarker in developing individualized treatments for NSCLC patients.
authors.affiliation: Department of Oncology, First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121000, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Cheng
authors.forename: Minwen
authors.initials: M
authors.lastname: Ha
authors.forename: Yadi
authors.initials: Y
authors.lastname: Wang
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.forename: Junchen
authors.initials: J
authors.lastname: Chen
authors.forename: Yue
authors.initials: Y
authors.lastname: Wang
authors.forename: Chunyan
authors.initials: C
authors.lastname: Tong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide; D012044:Regression Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D004268:DNA-Binding Proteins; D014747:Vinblastine; C071447:ERCC1 protein, human; D004720:Endonucleases; D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine
references.citation: Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66
references.pmid: 11602373
references.citation: Anticancer Res. 2010 Sep;30(9):3223-32
references.pmid: 20944091
references.citation: Science. 2009 Dec 18;326(5960):1698-701
references.pmid: 19965384
references.citation: Hum Mol Genet. 2007 Oct 1;16(19):2333-40
references.pmid: 17855454
references.citation: Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6
references.pmid: 16224397
references.citation: Ann Oncol. 2004 Aug;15(8):1194-203
references.pmid: 15277258
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6212-7
references.pmid: 16144923
references.citation: Respirology. 2008 Jun;13(4):510-7
references.pmid: 18494946
references.citation: J Clin Oncol. 2004 Jul 1;22(13):2594-601
references.pmid: 15173214
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Int J Gynecol Cancer. 2008 Jul-Aug;18(4):702-10
references.pmid: 17961161
references.citation: J Thorac Oncol. 2010 Feb;5(2):260-74
references.pmid: 20101151
references.citation: Lung Cancer. 2002 Dec;38(3):217-27
references.pmid: 12445742
references.citation: Eur J Hum Genet. 2007 Sep;15(9):967-73
references.pmid: 17522621
references.citation: Ann Oncol. 2007 Mar;18(3):504-9
references.pmid: 17322540
references.citation: Oncology. 2002;63(2):105-14
references.pmid: 12239444
references.citation: N Engl J Med. 2006 Sep 7;355(10):983-91
references.pmid: 16957145
references.citation: Ann Oncol. 2007 Feb;18(2):317-23
references.pmid: 17079694
references.citation: Clin Lung Cancer. 2007 May;8(6):369-75
references.pmid: 17562237
references.citation: Lung Cancer. 2008 Jun;60(3):325-31
references.pmid: 18440088
references.citation: Lung Cancer. 2010 Jan;67(1):101-7
references.pmid: 19361884
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Clin Cancer Res. 2008 Mar 15;14(6):1797-803
references.pmid: 18347182
references.citation: Lung Cancer. 2007 May;56(2):281-8
references.pmid: 17222938
references.citation: Cancer Res. 1988 Aug 15;48(16):4484-8
references.pmid: 3395999